Brilique 90 mg film-coated tablets
Each film-coated tablet contains 90 mg ticagrelor.
For the full list of excipients, see section 6.1.
Film-coated tablet (tablet).
Round, biconvex, yellow tablets marked with '90' above 'T' on one side and plain on the other.
Brilique, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non ST elevation myocardial infarction [NSTEMI] or ST elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
For further information, please refer to section 5.1.
Posology
Brilique treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily.
Patients taking Brili
